Compare CTRE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRE | BLCO |
|---|---|---|
| Founded | 2013 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Ophthalmic Goods |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | CTRE | BLCO |
|---|---|---|
| Price | $36.18 | $16.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 14 |
| Target Price | ★ $39.50 | $17.31 |
| AVG Volume (30 Days) | ★ 1.8M | 408.9K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ 90.43 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | $428,478,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $23.27 | $8.08 |
| Revenue Next Year | $27.02 | $5.77 |
| P/E Ratio | $26.99 | ★ N/A |
| Revenue Growth | ★ 59.24 | 6.23 |
| 52 Week Low | $24.79 | $10.45 |
| 52 Week High | $38.32 | $18.99 |
| Indicator | CTRE | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 60.98 |
| Support Level | $35.83 | $16.39 |
| Resistance Level | $38.18 | $17.41 |
| Average True Range (ATR) | 0.68 | 0.46 |
| MACD | -0.21 | 0.06 |
| Stochastic Oscillator | 14.86 | 72.71 |
CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.